european society for paediatric nephrology

ESPN RESEARCH CONFERENCE

FLORENCE 2025
20-22 MARCH



OIC group

Metabolic bone disease and cardiovascular health in kidney disorders

PROGRAMME

european society for paediatric nephrology

CONTENTS

To encourage open communication, each member of the ESPN Research Conference agrees that any information presented at the Conference, whether in a formal talk, poster session, or discussion, is a private communication from the individual making the contribution and is presented with the restriction that such information is not for public use.

Prior to quoting or publishing any such information presented at the ESPN Research Conference in any publication, written or electronic, written approval of the contributing member must first be obtained. The audio or video recording of lectures by any means, the photography of slide or poster material, and printed or electronic quotes from papers, presentations and discussion at the Conference without written consent of the contributing member is prohibited. Scientific publications are not to be prepared as emanating from the Conference. Authors are requested to omit references to the Conference in any publication, written or electronic. These restrictions apply to each member of the Conference and are intended to cover social networks, blogs, tweets or any other publication, distribution, communication or sharing of information presented or discussed at the Conference. Guests are not permitted to attend the Conference lectures and discussion sessions. Each member of the Conference acknowledges and agrees to these restrictions when registration is accepted and as a condition of being permitted to attend the Conference. Although the Conference staff will take reasonable steps to enforce the restrictions against recording and photographing presentations, each member of the Conference assumes sole responsibility for the protection and preservation of any intellectual property rights in such member's contributions to the Conference.



Dear colleagues and dear friends,

We are excited to host you in the 1st ESPN Research Conference from March 20-22, 2025. During the next 2 days, scientists and clinicians are going to share unrivaled research and inspiring new ideas on the interplay of bones, kidneys, and cardiovascular system in health and disease.

The program ensures extensive discussions during the scientific sessions and networking activities to advance research ideas, promote collaboration, and establish the culture innovation.

We have reserved a large space for free oral presentations and posters allowing young and more experienced researchers to present and discuss their latest work with experts in the field.

Let's enjoy discussion, exchange ideas and gain insights into disease mechanisms and effects of novel treatments in a stimulating retreat atmosphere!

Thank you for coming to Florence!

Prof. Dieter Haffner
ESPN President

PD Dr. Maren Leifheit-Nestler
Scientific Co-Chair

Prof. Stella Stabouli
Scientific Co-Chair

THURSDAY, 20 MARCH 2025

14:00 *Arrival at the Hotel Mediterraneo and check-in*
16:00

MEETING ROOM SALONE DEGLI OCEANI

16:00 Welcome from the ESPN President
Dieter Haffner *(Hannover Medical School, Germany)*

16:05 Introduction from the Chairs
Stella Stabouli *(Aristotle University of Thessaloniki, Greece)* and
Maren Leifheit-Nestler *(Hannover Medical School, Germany)*

16:10 KEYNOTE SESSION
17:30 Discussion Leaders: **Stella Stabouli** *(Aristotle University of Thessaloniki, Greece)* and **Maren Leifheit-Nestler** *(Hannover Medical School, Germany)*

16:10 Phosphate homeostasis and endocrine regulators
Clemens Bergwitz *(Yale University School of Medicine, USA)*

16:40 Discussion

16:50 Understanding of metabolic bone diseases: lessons from genetic animal models
Carsten Wagner *(University of Zurich, Switzerland)*

17:20 Discussion

17:30 POSTER SESSION 1
18:30 *Coffee will be served during the poster session*



THURSDAY, 20 MARCH 2025

MEETING ROOM SALONE DEGLI OCEANI

18:30 – 20:00 **DIAGNOSIS AND MANAGEMENT OF CHILDREN AND ADULTS WITH X-LINKED HYPOPHOSPHATEMIA: WHAT'S NEW? + BEST ABSTRACTS**
Discussion Leaders: **Dieter Haffner** *(Hannover Medical School, Germany)* and **Jun Oh** *(University Medical Center Hamburg-Eppendorf, Germany)*

18:30 New XLH European Guidelines: evolving clinical practice
Dieter Haffner *(Hannover Medical School, Germany) and*
Francesco Emma *(Bambino Gesù Children's Hospital, Rome, Italy)*

19:15 Discussion

19:30 Markers of metabolic bone disease in children with X-linked hypophosphatemia: a real-world study in Germany and Switzerland
Ineke Böckmann *(Hannover Medical School, Germany)*

19:40 Discussion

19:45 Naturally occurring stable calcium isotopes predict changes in bone (de)mineralisation in children and young adults with CKD and on dialysis
Rukshana Shroff *(UCL Great Ormond Street Hospital and Institute of Child Health, London, United Kingdom)*

19:55 Discussion

20:00 *Dinner at the hotel's restaurant*

FRIDAY, 21 MARCH 2025

07:30 *Breakfast*
08:45

MEETING ROOM SALONE DEGLI OCEANI

09:00 **CARDIOVASCULAR SYSTEM IN KIDNEY DISEASES**
10:30 Discussion Leaders: **Dieter Haffner** *(Hannover Medical School, Germany)* and **Marc Vervloet** *(Radboud University, The Netherlands)*

09:00 Cardiovascular biomarkers: FGF23, klotho and beyond (cause or marker)
Justine Bacchetta *(University of Lyon, France)*

09:20 Discussion

09:30 Functional analyses of the calcium-sensing receptor (CaSR) in the cardiac system and the impact of high phosphate
Louise Baer *(Hannover Medical School, Germany)*

09:40 Discussion

09:45 Cardiovascular health in CKD: addressing the gaps
Rukshana Shroff *(Great Ormond Street Institute of Child Health, University College London, UK)*

10:05 Discussion

10:15 High phosphate diet-induced cardiac dysfunction: importance of sodium-dependent phosphate cotransporters Pit1 and Pit2
Andrea Grund *(Hannover Medical School, Germany)*

10:25 Discussion

10:30 *Coffee break*
11:00



FRIDAY, 21 MARCH 2025

MEETING ROOM SALONE DEGLI OCEANI

11:00 – 12:30 **PATHOPHYSIOLOGICAL INSIGHTS INTO METABOLIC BONE DISEASES**
Discussion Leaders: **Justine Bacchetta** *(University of Lyon, France)* and **Clemens Bergwitz** *(Yale University School of Medicine, USA)*

11:00 Insight of the development of myopathy and future treatments
Philippos Mourikis *(Necker Institute for Sick Children, France)*

11:20 Discussion

11:30 Bone and vessel crosstalk
Marc Vervloet *(Radboud University, The Netherlands)*

11:50 Discussion

12:00 Cystinosis metabolic bone disease: pathogenesis and outcome
Dieter Haffner *(Hannover Medical School, Germany)*

12:20 Discussion

12:30 – 12:45 *Group photo*

12:45 – 14:00 *Lunch at the hotel's restaurant*

14:00 – 15:00 *Free time*

FRIDAY, 21 MARCH 2025

MEETING ROOM SALONE DEGLI OCEANI

15:00 – 16:30 NOVEL AND FUTURE THERAPEUTIC MEASURES FOR METABOLIC BONE DISEASE AND CARDIOVASCULAR SYSTEM
Discussion Leaders: **Maren Leifheit-Nestler** *(Hannover Medical School, Germany)* and **Franz Schaefer** *(University of Heidelberg, Germany)*

15:00 Novel measures for metabolic bone disease: PH1-3 and beyond
Michiel J.S. Oosterveld *(University of Amsterdam, The Netherlands)*

15:20 Discussion

15:30 Impact of the enzyme replacement therapy, INZ-701, in children with ENPP1 deficiency: experience from an expanded access program
Mattia Parolin *(University of Padua, Italy)*

15:40 Discussion

15:45 The heart in Fabry disease
Kristina Sonnenschein *(Hannover Medical School, Germany)*

16:05 Discussion

16:15 Musclin as a new marker for muscle health in nephropathic cystinosis
Malgorzata Szaroszyk *(Hannover Medical School, Germany)*

16:25 Discussion

16:30 – 18:00 POSTER SESSION 2
Coffee will be served during the poster session



FRIDAY, 21 MARCH 2025

MEETING ROOM SALONE DEGLI OCEANI

18:00 **EXPERIMENTAL TRANSLATIONAL STUDIES I**
19:30 Discussion Leaders: **Michiel J.S. Oosterveld** *(University of Amsterdam, The Netherlands)* and **Rukshana Shroff** *(Great Ormond Street Institute of Child Health, University College London, UK)*

18:00 Understanding the pathophysiological signaling in cardiovascular disease
Jakob Völkl *(Johannes Kepler University Linz, Austria)*

18:20 Discussion

18:30 Development and validation of a vascular organoid model for pediatric chronic kidney disease-associated vascular remodeling and calcifications
Julie Bernardor *(University Hospital of Nice, France)*

18:40 Discussion

18:45 Mitochondrial involvement in cardiac, muscle and kidney disease
Francesco Emma *(Bambino Gesù Children's Hospital, Italy)*

19:05 Discussion

19:15 Peritoneal infusion of microplastics induces over-expression of GDF15 in kidney and heart in mice
Marta Ferrecchi *(University of Genoa, Italy)*

19:25 Discussion

19:30 *Free time*
20:00

20:30 *Dinner at "Finisterrae" restaurant*

SATURDAY, 22 MARCH 2025

07:30 *Breakfast*
08:45

MEETING ROOM SALONE DEGLI OCEANI

09:00 **CLINICAL SCENARIOS**
10:30 Discussion Leaders: **Oh Jun** *(University Medical Center Hamburg-Eppendorf, Germany)* and **Stella Stabouli** *(Aristotle University of Thessaloniki, Greece)*

09:00 Clinical scenarios in pediatric kidney diseases with a focus on cardiovascular and bone health
Franz Schaefer *(University of Heidelberg, Germany)*

09:20 Discussion

09:30 Longitudinal relationship between albuminuria and renal function in children and young adults from the general population
Valentina Gracchi *(Beatrix Children's Hospital - University Medical Center Groningen, The Netherlands)*

09:40 Discussion

09:45 Clinical scenarios in adults with CKD and cardiovascular outcomes
Beatriz Fernández-Fernández *(IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain)*

10:05 Discussion

10:15 Vitamin K2 profile in young patients with renal replacement therapy: link with vascular health?
Lou Cryns *(University of Antwerp, Belgium)*

10:25 Discussion

10:30 *Coffee break*
11:00



SATURDAY, 22 MARCH 2025

MEETING ROOM SALONE DEGLI OCEANI

11:00 – 12:30 **EXPERIMENTAL TRANSLATIONAL STUDIES II**
Discussion Leaders: **Jakob Völkl** *(Johannes Kepler University Linz, Austria)* and **Carsten Wagner** *(University of Zurich, Switzerland)*

11:00 Genetically modified animal models
Guillaume Courbon *(INSERM, University of Saint Etienne, France)*

11:20 Discussion

11:30 Identification of phenotype modifier gene variants overrepresented in familial hypomagnesemia with hypercalciuria and nephrocalcinosis with a more aggressive renal phenotype
Julieta Torchia *(Vall d'Hebron Institute of Research, Barcelona, Spain)*

11:40 Discussion

11:45 Genome editing (CRISPR/Cas and others) in kidney diseases
Miguel A. Garcia González *(University of Santiago de Compostela, Spain)*

12:05 Discussion

12:15 Applying LNP/mRNA technology to therapy of cystinosis
Paul Goodyer *(Research Institute of the McGill University Health Centre, Montreal, Canada)*

12:25 Discussion

12:30 – 12:45 *Farewell*

12:45 – 14:00 *Luch at the hotel's restaurant*

POSTER SESSION

P01 Naturally occurring stable calcium isotopes predict changes in bone (de) mineralisation in children and young adults with CKD and on dialysis
Alexander D. Lalayiannis[1], Anton Eisenhauer[2], Ana Kolevica[2], Alexander Heuser[2], Varvara Askiti[3], Amrit Kaur[1], Manish Sinha[1], David Milford[1], Mary Fewtrell[1], Rukshana Shroff[1] *([1]United Kingdom, [2]Germany, [3]Greece)*

P02 Fanconi-Bickel syndrome: a rare cause of pRTA with significant risk of bone fractures and deformities
Bahriye Atmis, Aysun Karabay Bayazıt, Deniz Kor, Fatma Derya Bulut, Neslihan Önenli Mungan *(Turkey)*

P03 Secondary hyperparathyroidism and brown tumors in pediatric dialysis patients: a critical call for treatment adherence
Bahriye Atmis, Zahide Orhan Ok, Çağla Çağlı Pişkin, Aysun Karabay Bayazıt *(Turkey)*

P06 Alterations of bone and mineral metabolism during CKD progression and impact of kidney replacement therapy: a real-world pediatric study
Anna Tschirner, Weber Hannah, Schermuly Katharina, Böckmann Ineke, Kanzelmeyer Nele, Drube Jens, Haffner Dieter, Leifheit-Nestler Maren *(Germany)*

P07 Markers of metabolic bone disease in children with X-linked hypophosphatemia: a real-world study in Germany and Switzerland
Ineke Böckmann, Maren Leifheit-Nestler, Schlingmann Karl Peter, Freiberg Clemens, Weitz Marcus, Dunstheimer Desiree, John Ulrike, Wühl Elke, Schnabel Dirk, Haffner Dieter *(Germany)*

P09 Functional analyses of the calcium-sensing receptor (CaSR) in the cardiac system and the impact of high phosphate
Louise Baer, Andrea Grund, Dieter Haffner, Maren Leifheit-Nestler *(Germany)*

P10 High phosphate diet-induced cardiac dysfunction: Importance of sodium-dependent phosphate cotransporters Pit1 and Pit2
Andrea Grund, Maren Leifheit-Nestler, Dieter Haffner *(Germany)*

P12 P-cresol and p-cresol sulphate and clinical outcomes in CKD: systematic review
Patrick Clarke, Matthew J. Harmer *(United Kingdom)*

P13 Impact of the enzyme replacement therapy, INZ-701, in children with ENPP1 deficiency: experience from an expanded access program
Mattia Parolin[1], Belen Ferrer[2], Ruba Rizik[3], Kurt C. Gunter[4] *([1]Italy, [2]Spain, [3]Israel, [4]USA)*

P14 Can oral bisphosphonates counteract mineral bone disease in Lowe syndrome? A case series of three patients
Elisa Manieri, Guido Zavatta, Federico Baronio, Andrea Pasini, Claudio La Scola *(Italy)*



POSTER SESSION

P15 Musclin as a new marker for muscle health in nephropathic cystinosis
Malgorzata Szaroszyk, Lars Leemhuis, Dieter Haffner, Maren Leifheit-Nestler *(Germany)*

P16 Developing an organoid model of podocin-related nephrotic syndrome using patient-derived induced pluripotent stem cells
Robert Matthes, Mansoureh Tabatabaeifar, Sabine Jung-Klawitter, Franz Schaefer *(Germany)*

P18 Applying LNP/mRNA technology to therapy of cystinosis
Paul Goodyer, Elena Torban *(Canada)*

P19 Development and validation of a vascular organoid model for pediatric chronic kidney disease-associated vascular remodeling and calcifications
Matthieu Rouleau[1], Justine Simonin[1], Elise Larché[1], Zakariya Caillot[1], Claudine Blin-Wakkach[1], Maria Bartosova[2], Claus Peter Schmitt[2], Julie Bernardor[1] *([1]France, [2]Germany)*

P20 Effects of exercise in chronic kidney disease: crosstalk between muscle and kidney
Katharina Maier, Malgorzata Szaroszyk, Dieter Haffner, Maren Leifheit-Nestler *(Germany)*

P21 Peritoneal infusion of microplastics induces over-expression of GDF15 in kidney and heart in mice
Marta Ferrecchi, Decimo Silvio Chiarenza, Micaela Gentile, Paolo Cravedi, Gabriele Mortari, Pasquale Esposito, Daniela Verzola, Enrico Verrina, Noemi Rumeo, Edoardo La Porta *(Italy)*

P22 Identification of phenotype modifier gene variants overrepresented in familial hypomagnesemia with hypercalciuria and nephrocalcinosis with a more aggressive renal phenotype
Julieta Torchia, Mónica Vall-Palomar, Jordi Morata, Monica Duran, Mireia Ferrer, Alex Sanchez, Gerard Cantero-Recasens, Gema Ariceta, Anna Meseguer, Cristina Martínez *(Spain)*

P23 Coronavirus viroporins regulate CFTR trafficking and function
Aparna Renigunta, Jonathan Schlegel, John Ziebuhr, Vijay Renigunta, Stefanie Weber *(Germany)*

P24 p-glycoprotein-1(abcb1) along with adenylate kinase (ak1) mediates nucleotide -gated channel regulation of kcnj1
Vijay Renigunta[1], Imran Shaikh[1], Nils Renfordt[1], Siegfried Waldegger[2], Martin Koemhoff[1], Stefanie Weber[1], Aparna Renigunta[1] *([1]Germany, [2]Austria)*

P25 Biomarkers predictive for the renal graft survival - Romanian experience
Andreea Liana Bot (Rachisan) *(Romania)*

POSTER SESSION

P28 Vitamin K2 profile in young patients with renal replacement therapy: link with vascular health?
Lou Cryns[1], Van Eyck Annelies[1], Leon Schurgers[2], Dominique Trouet[1] *([1]Belgium, [2]The Netherlands)*

P29 Variant analysis in a cohort of pediatric patients with congenital anomalies of the kidney and urinary tract (CAKUT) after extended next generation sequencing (NGS)
Dana Blasi, Mansoureh Tabatabaeifar, Christian Sutter, Franz Schaefer *(Germany)*

P30 Insulin resistance in young patients with autosomal dominant polycystic kidney disease
Olil Van Reeth, Inès Vanderheyden, Jean-Paul Decuypere, Rudi Vennekens, Peter Janssens, François Jouret, Djalila Mekahli *(Belgium)*

P31 Longitudinal relationship between albuminuria and renal function in children and young adults from the general population
Valentina Gracchi[1], Hiddo Lambers Heerspink[2], Henk Groen[3], Richard Coward[2], Henkjan Verkade[1] *([1]The Netherlands, [2]United Kingdom)*

P32 Pediatric nephrolithiasis-clinical manifestations and metabolic profiles from a dedicated multidisciplinary clinic
Shelly Levi, Roy Morag, Daniel Landau, Miriam Davidovits, Abigail Lazar, Lotem Goldberg, Efrat Talgam Horshi, Gili Koren, Adi Chezana, Yael Borovitz *(Israel)*

P33 Percutaneous kidney biopsy associated risks in children: a 10 years clinical experience
Donatella Simone, Diletta Domenica Torres, Vincenza Carbone, Luisa Santangelo, Marida Martino, Mario Giordano, Paolo Giordano *(Italy)*

P34 Evaluation of carnitine concentration in blood and urine in children with diseases of the kidneys and urinary tract
Agnieszka Jędzura, Paulina Wysocka-Wojakiewicz, Martyna Jasielska, Anna Rokowska-Oleksa, Monika Dębowska, Katarzyna Sedlaczek, Piotr Adamczyk *(Poland)*

P35 Pediatric reference values for novel urinary biomarkers of kidney health in the HARP cohort
Hannah Weber, Katharina Schermuly, Anna Tschirner, Ineke Böckmann, Ulrich Baumann, Anibh M. Das, Nele Kanzelmeyer, Jens Drube, Dieter Haffner, Maren Leifheit-Nestler *(Germany)*

P36 Office blood pressure and obesity in children with X-linked hypophosphatemia
Ineke Boeckmann, Maren Leifheit-Nestler, Mirko Rehberg, Marcus Weitz, Ulrike John, Ludwig Patzer, Miroslav Zivicnjak, Elke Wühl, Dirk Schnabel, Dieter Haffner *(Germany)*



POSTER SESSION

P37 Long-term follow-up of patients with cyp24a1, slc34a1 and slc34a3 mutations: a retrospective study
Ruth Schreiber, Asaf Lebel, Shelly Levi *(Israel)*

P38 Obesity as a risk factor for kidney injury in a cohort of children in treatment for acute lymphoblastic leukemia: a multicenter retrospective analysis
Miriana Guarino, Paolo Giordano, Mario Giordano, Letizia Pomponia Brescia, Nicola Santoro, Francesco Chiarelli, Valerio Cecinati *(Italy)*

P39 Impact of mineral bone disease on quality of life in children with stage 5 chronic kidney disease
Branko Lutovac[1], Brankica Spasojevic[2] *([1]Montenegro, [2]Serbia)*

P40 Regulation of serum parameters of renal osteodystrophia and hypertension in pediatric patients on chronic hemodialysis
Kristina Matijas, Mirjana Cvetkovic, Dusan Paripovic, Gordana Milosevski-Lomic, Ivana Gojkovic, Ana Petrovic, Milica Vukanovic, Tanja Gaus, Brankica Spasojevic *(Serbia)*

european society for paediatric nephrology

HOTEL MAP and SPONSOR DIRECTORY MEETING ROOM "SALONE DEGLI OCEANI" - 1ST FLOOR



Desk number	Company
1	AVANZANITE
2	INOZYME
3	RENIBUS
4	BAYER



ACKNOWLEDGEMENTS

Thank you to all our Sponsors

GOLD SPONSOR

Bayer

SILVER SPONSOR

Chiesi
global rare diseases

SPONSORS

advicenne
Alnylam
avanzanite BIOSCIENCE
inozyme pharma
renibus therapeutics

NOTES



NOTES

NOTES

In Advicenne we are dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults

We are dedicated to improving patients' daily health and life and are committed to tackle the challenge of high unmet medical needs.

For more information, visit www.advicenne.com

Distal renal tubular acidosis is a rare kidney disorder that occurs when the kidneys are unable to effectively remove the buildup of circulating acids in the blood—a condition called acidosis—which leads to a metabolic imbalance. dRTA is a serious disorder, especially for paediatric patients. dRTA can be either genetically inherited or acquired. The inherited form of dRTA, also known as primary dRTA, is most common among infants and children, while the acquired form is more common in adults. Acquired dRTA can be due to autoimmune disorders, rheumatoid arthritis, or to certain medications. An estimated 30,000 patients in Europe and 20,000 patients in the United States suffer from dRTA.

Advicenne

262, rue du Faubourg Saint-Honoré,
75008 Paris, France
+33 (0)1 85 73 36 20
www.advicenne.com
contact@advicenne.com

FCSIB-003-25-02

Alnylam® | The home of RNAi

If home is where the heart is, our heart is our innovative RNAi therapeutics.

Discover more about the home of RNAi, including:

The RNAi-based medicines we pioneered over 20 years ago[1]

The world's first approved RNAi therapeutic we launched in 2018[1]

Our RNAi research areas of focus:[2]

- Transthyretin amyloidosis
- Rare diseases
- Cardiovascular diseases
- Metabolic diseases
- Neurological diseases

Visit www.alnylamconnect.eu to access the latest information about Alnylam from our team

RNAi, ribonucleic acid interference.

References:

1. Alnylam Pharmaceuticals. Our science. Accessed February 2025. https://www.alnylam.com/our-science/the-science-of-rnai/
2. Alnylam Pharmaceuticals. Our pipeline. Accessed February 2025. https://www.alnylam.com/alnylam-rnai-pipeline

For healthcare professionals only

Sponsored and funded by Alnylam Pharmaceuticals. Email: MedInfo@alnylam.com February 2025 NP-INTX-00165

We are Making a Rare Difference

We act with purpose, as a family-owned
Certified B Corporation **committed to rare diseases**

Follow us on

www.chiesirarediseases.com
Date of preparation: June 2024 | ALL_24_524

Chiesi
global rare diseases

Certified B Corporation

european society for paediatric nephrology



CONGRESS VENUE
Grand Hotel Mediterraneo
Lungarno del Tempio, 44
50121 Florence - Italy

ORGANISING SECRETARIAT

oic group

Viale della Giovine Italia, 17
50122 Florence - Italy
Tel. +39 055 50351 | Fax +39 055 5001912
www.oic.it

SCIENTIFIC INFORMATION:
ESPNResearchConference@oic.it

GENERAL INFORMATION:
infoESPNResearchConference@oic.it

REGISTRATION and HOTEL INFORMATION:
regESPNResearchConference@oic.it

SPONSORSHIP OPPORTUNITIES:
sponsorESPNResearchConference@oic.it